First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
But this comes in second-line breast cancer, a use the group isn’t pursuing.
The company admits defeat with zelenectide.
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
Ascentage hopes to become a new force in BTK.
Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
